• Bio-Rad swung to third-quarter 2026 net income of $458.6 million, substantially helped by a fair-value change in its Sartorius AG investment.
• Operations turned to a $49.7 million loss, while net sales rose to $656.4 million from a year earlier.
• Net cash from operations fell 20% year over year to $96.4 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bio-Rad Laboratories Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202611041615BIZWIRE_USPR_____20261104_BW537666) on November 04, 2026, and is solely responsible for the information contained therein.